ArticlePediatric endocrinology, diabetes, and metabolism2025
Cross-sectional evaluation of people with type 1 diabetes participating in the GoPump Structured Diabetes Education Program during "Insulin Pump Weeks".
Article in Pediatric endocrinology, diabetes, and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Glucagon-like peptide-1 agonists' effects on glycemic control, weight loss, and beta cells function in type 1 diabetes.Frontiers in endocrinology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite advances in therapy, most persons with type 1 diabetes (PwT1Ds) do not achieve treatment goals. Education is fundamental to the care of PwT1Ds treated with continuous subcutaneous insulin infusion (CSII). AIM OF THE STUDY: To evaluate PwT1Ds treated with CSII and receiving in-hospital education and to identify factors associated with treatment effectiveness. MATERIAL AND
methodsThis cross-sectional study included adults with type 1 diabetes (T1D), who received diabetes education using the proprietary Structured Diabetes Education Program, GoPump, during "Insulin Pump Weeks" in 2022-2023. Metabolic control of diabetes was evaluated. Reports from personal insulin pumps, blood glucose meters, and continuous glucose monitoring (CGM) systems were assessed.
resultsData from 107 individuals with a median age of 26.7 years (Q1-Q3: 19.0-30.8) were analysed, including 65 women (60.7%). The median duration of T1D was 13 years (Q1-Q3: 10.0-18.0), and the median duration of personal insulin pump use was 8 years (Q1-Q3: 5.0-12.0). The median body mass index was 23.9 kg/m². CGM was used by 52.3% of individuals. The median time in range (TIR) was 57.0% (Q1-Q3: 45.0-69.5%), and the median glycated haemoglobin (HbA1c) level was 7.9% (Q1-Q3: 6.8-8.5%). A positive correlation was found between age and TIR (rs = 0.42, p = 0.001). The use of temporary basal rate and dual-wave and square bolus features was positively correlated with TIR (rs = 0.34, p = 0.012 and rs = 0.31, p = 0.021, respectively) and inversely with time above range > 250 mg/dl (rs = -0.37, p = 0.007 and rs = -0.27, p = 0.045, respectively). Lower HbA1c levels were observed in individuals with a higher number of daily boluses (rs = -0.33, p = 0.001).
conclusionsIn the study cohort, older age, more frequent use of advanced insulin pump features, and a higher number of daily boluses were associated with better glycaemic control in adults with T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.